JCI - Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
J. Clin. Invest. 113:11 doi:10.1172/JCI20911 [Go to this article.]

Options: View larger image (or click on image)

Figure 3

GCGR ASO treatment results in α cell hyperplasia. Glucagon immunostaining of representative pancreas sections from 11- to 12-week-old db^+/?, ob/ob, db/db mice, and ZDF rats, which had been treated twice per week (every 3.5 days) by subcutaneous injection with control ASO 141923 (upper panels) or GCGR ASO 180475 (lower panels) at 25 mg/kg for 9 total doses. Original magnification, db^+/?, ∞40; others, ∞20).